← Leaderboards
Albert J. Wong
Children'S Hospital Of Philadelphia
$7,669,833
Attributed
$8,443,892
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,443,892 · 7
By mechanism
R01$6,251,040 · 4
RC2$1,548,119 · 1
R21$401,823 · 1
P01$242,910 · 1
Top collaborators
- Paul Graham Fisher2 shared
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Katherine A High$15,374,120
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaProtein Tyrosine KinaseGlioblastomaHuman TissueProteinsEpidermal Growth Factor ReceptorCellsTumorAngiogenesisCell ProliferationPhosphorylationMitogen Activated Protein KinasePhenotypePropertyPharmaceutical PreparationsBiological Signal TransductionReceptorMalignant NeoplasmsIntermolecular InteractionSuccessBaseCell FractionationCancer CellFamily
Grant awards (27)
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers$180,637
R21 · FY2022 · CA · contact PI
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers$221,186
R21 · FY2021 · CA · contact PI
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas$292,056
R01 · FY2011 · CA · contact PI
A Phase I Study of EGFRvIII Peptide Vaccination (CDX-110) after Conventional Radi$770,133
RC2 · FY2010 · CA
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas$301,055
R01 · FY2010 · CA · contact PI
A Phase I Study of EGFRvIII Peptide Vaccination (CDX-110) after Conventional Radi$777,986
RC2 · FY2009 · CA
Novel Effectors of GRB2 in Human Glial Tumors$316,072
R01 · FY2009 · CA · contact PI
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas$301,022
R01 · FY2009 · CA · contact PI
Novel Effectors of GRB2 in Human Glial Tumors$316,005
R01 · FY2008 · CA · contact PI
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas$300,991
R01 · FY2008 · CA · contact PI
Novel Effectors of GRB2 in Human Glial Tumors$315,940
R01 · FY2007 · CA · contact PI
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas$300,861
R01 · FY2007 · CA · contact PI
Novel Effectors of GRB2 in Human Glial Tumors$325,311
R01 · FY2006 · CA · contact PI
The Role of JNK in Glial Tumor Pathogenesis$305,790
R01 · FY2006 · CA · contact PI
The Role of JNK in Glial Tumor Pathogenesis$314,393
R01 · FY2005 · CA
Novel Effectors of GRB2 in Human Glial Tumors$243,439
R01 · FY2005 · CA
Novel Effectors of GRB2 in Human Glial Tumors$102,327
R01 · FY2005 · CA
The Role of JNK in Glial Tumor Pathogenesis$314,393
R01 · FY2004 · CA
The Role of JNK in Glial Tumor Pathogenesis$314,393
R01 · FY2003 · CA
NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS$303,555
R01 · FY2003 · CA
The Role of JNK in Glial Tumor Pathogenesis$314,393
R01 · FY2002 · CA
NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS$296,374
R01 · FY2002 · CA
NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS$288,148
R01 · FY2001 · CA
ALTERED EGF RECEPTORS IN HUMAN GLIAL TUMORS$205,374
R01 · FY2001 · CA
NOVEL EFFECTORS OF GRB2 IN HUMAN GLIAL TUMORS$279,757
R01 · FY2000 · CA
SIGNAL TRANSDUCTION PATHWAYS IN MEDULLOBLASTOMA$242,910
P01 · FY2000 · NS
ALTERED EGF RECEPTORS IN HUMAN GLIAL TUMORS$199,391
R01 · FY2000 · CA